MED12L/MED12 amplification is enriched in BRCA2‐mutant prostate cancer with IDC‐P, particularly in cases associated with a poor prognosis. MYC amplifications is enriched in BRCA2‐mutant prostate cancer with IDC‐P. This evidence concerns the gene BRCA2 and prostate carcinoma.